ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial tests an oral integrin α4β7 inhibitor for Crohn’s disease, a new small-molecule approach aiming to block gut-specific immune cell trafficking similar to existing biologic anti‑integrin drugs. If effective and safe, it could become another treatment option for people with moderate-to-severe CD.
Who Should Pay Attention
Adults with moderately to severely active Crohn’s disease, patients who have failed or are intolerant of prior therapies (including biologics), clinicians treating IBD, and researchers in IBD drug development.
Study Snapshot
Story typeClinical Reference
Trial phasePhase 2
Enrollment385 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
Phase 2 randomized, double-blind, placebo-controlled trial of MORF-057 (an oral small molecule designed to selectively inhibit integrin α4β7) in adults with moderately to severely active Crohn’s disease.
The study has a 14-week induction period comparing three blinded MORF-057 dosing regimens to placebo, followed by a 38-week open-label maintenance period with all participants receiving MORF-057, and an optional 52-week long-term extension. Primary outcome is endoscopic response at Week 14 measured by SES-CD (≥50% decrease).
The trial is recruiting adults (18–85) with active CD who meet CDAI and SES-CD thresholds and who have had inadequate response or intolerance to prior therapies; prior treatment with vedolizumab or other integrin inhibitors is an exclusion.
Key design elements (randomized, double-blind, placebo-controlled, multicenter) and planned enrollment (~385) are reported on the clinicaltrials.gov record. This summary is based on the clinicaltrials.gov study record (trial registration) and does not represent results or findings.
Keep In Mind
This is a trial registration record (Phase 2, recruiting) and reports study design and eligibility but not results. The investigational drug (MORF-057) is excluded in people previously treated with vedolizumab or other integrin inhibitors, so prior exposure may affect eligibility. Participation requires meeting specific clinical and endoscopic disease thresholds.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorMorphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Trial IDNCT06226883
Study typeInterventional
Trial phasePhase 2
Enrollment385 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 20, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
This trial tests whether adding an FXR agonist (LY4395089) to mirikizumab improves endoscopic response in people with moderate–severe Crohn's disease. Results could influence future combination treatment strategies and...
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...